Health Care

UVM researcher paves way for revolutionary RSV treatment

Photo from UVM website

Sean Diehl, Ph.D., associate professor of microbiology and molecular genetics at the University of Vermont’s Larner College of Medicine, has played a significant role in advancing Respiratory Syncytial Virus (RSV) prevention, a UVM statement said.

Diehl’s research influenced the development of a recent groundbreaking RSV antibody treatment, Beyfortus (nirsevimab), owned and distributed by pharmaceutical company AstraZeneca, in conjunction with Sanofi.

RSV, a common respiratory virus with serious implications for infants and young children, has long posed public health challenges. Diehl’s collaboration with Amsterdam University Medical Centers (UMC) in the early 2000s led to notable progress in RSV prevention.

Diehl’s journey began in 2010 when he and fellow researchers at Amsterdam UMC identified the antibody D-25, showing potential for protecting newborns from RSV. Over more than a decade, Diehl and his collaborators refined this discovery, using practical methodologies to enhance its effectiveness. The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have now endorsed the incorporation of the antibody drug, Sanofi and AstraZeneca’s Beyfortus (nirsevimab), into the vaccination schedule for children under six.

Nirsevimab is a passive immunization that delivers a single dose of a long-acting monoclonal antibody, neutralizing RSV’s ability to infect cells. This approach offers direct protection against the virus without requiring the immune system activation typical of active vaccines. Importantly, it also allows the recipient’s immune system to develop its own protective responses to RSV.

Diehl’s significant contributions lie in the development of methodologies that contributed to the success of the vaccine. His efforts have propelled RSV prevention forward and paved the way for antibody therapies against various infectious diseases, including Zika virus and dengue. Beyfortus (nirsevimab) will become part of the CDC’s Vaccines for Children program during the upcoming winter 2023 RSV season, providing protection against the virus.

Categories: Health Care, Press Release

4 replies »

  1. Vaccines are population controls.
    Try terrain theory. It addresses and cures illness ACTUALLY.
    Poisons, toxins, pesticides, pollution, poisons in food, water and air… no impact at all, right?
    Overweight eating the wrong foods is a setup for hospital care and beaucoup bucks for the sickness industry counting on you wanting to be cured, instead of walking that road, literally yourself, pulling up your big girl and boy panties and holding yourself accountable for the poisons you allow into your body, both intentionally and unintentionally.

    Pasteur lied: No viruses exist.
    The average virologist gets 4-5 hours of class time on virology. That’s ALL they got.
    Antoine Beauchamp couldn’t duplicate Pasteur’s virus experiments. And Pasteur confessed to lying.
    THE REAL ANTHONY FAUCI covers this in one of the well researched chapters in RFK Jr’s book.
    Don’t be a chump or a guinea pig.
    Let eugenics take a rest as that is all vaccines are – population control.

  2. I don’t see any evidence in this article that demonstrates Nirsevimab is safe. And RSV is generally a mild infection per the Mayo Clinic “Respiratory syncytial virus (RSV) causes infections of the lungs and respiratory tract. It’s so common that most children have been infected with the virus by age 2….In adults and older, healthy children, respiratory syncytial virus (RSV) symptoms are mild and typically mimic the common cold. Self-care measures are usually all that’s needed to relieve any discomfort.”

    So why put it on the CDC’s childhood schedule adding to the risks of injection overload for children? Anyone who’s awake knows the story of vaccine injury and death.

    “Childhood vaccines are virtually never licensed based on trials that included a control group receiving an inert substance.

    It is categorically false to claim that “all vaccine trials” included an “immunologically inert” control. This is because most childhood vaccine trials used other vaccines as a control, which, by definition, are immunologically active.

    The use of vaccines as controls is highly concerning because the control vaccines were virtually never licensed based on a placebo-controlled trial – meaning “inert” per CDC/FDA. This is true even for trials of the first vaccine for a target disease. Hence, the safety of the subject or control vaccine was virtually never properly assessed in any clinical trial.

    For example, Prevnar-13 was licensed based on a trial comparing it to Prevnar-7, and Prevnar-7 was licensed based on a trial comparing it to another experimental vaccine. “Serious adverse events reported following vaccination in infants and toddlers occurred in 8.2% among Prevnar 13 recipients and 7.2% among Prevnar 7 recipients.” Meaning, equally safe by FDA standards. But equally unsafe by any other standard.”

  3. How many children will die or have serious side effects from this one?

  4. Dr. Pierre Kory recently interviewed by Greg Hunter (a veteran reporter who used to work for CNN yrs ago) Dr. Kory, among many other high caliber doctors and researchers, are censored, fired, decertified, and slandered when they produce facts and evidence of what is really happening in the medical community and why. I encourage all to view this interview and decide whether any corporate or medical university can ever be trusted again.